TONIX PHARMACEUTICALS HOLDING CORP. Increase (Decrease) in Accounts Receivable
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Increase (Decrease) in Accounts Receivable of $5.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-10
- TONIX PHARMACEUTICALS HOLDING CORP. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $2.99M.
- TONIX PHARMACEUTICALS HOLDING CORP. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $2.55M.
- TONIX PHARMACEUTICALS HOLDING CORP. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $2.79M.
- TONIX PHARMACEUTICALS HOLDING CORP. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $1.19M, a 27.39% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. increase (decrease) in accounts receivable for fiscal 2025 was $2.62M, a 28.89% decline from fiscal 2024.
- TONIX PHARMACEUTICALS HOLDING CORP. increase (decrease) in accounts receivable for fiscal 2024 was $3.68M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $5.53M 10-Q · filed 2026-08-10 | $8.32M derived: sum of 3 quarters · filed 2026-08-10 | $9.52M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $2.55M 10-Q · filed 2026-05-11 | $5.34M derived: sum of 2 quarters · filed 2026-05-11 | $6.53M derived: sum of 3 quarters · filed 2026-05-11 | $5.54M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.98M derived: sum of 2 quarters · filed 2026-03-12 | $2.99M derived: sum of 3 quarters · filed 2026-08-10 | $2.62M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $201.00K derived: sum of 2 quarters · filed 2026-08-10 | -$170.00K 10-Q · filed 2025-11-10 | -$1.47M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$992.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$1.36M 10-Q · filed 2026-08-10 | -$2.66M derived: sum of 3 quarters · filed 2026-08-10 | -$1.02M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$371.00K 10-Q · filed 2026-05-11 | -$1.67M derived: sum of 2 quarters · filed 2026-05-11 | -$27.00K derived: sum of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $344.00K derived: sum of 2 quarters · filed 2026-03-12 | $3.68M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.98M 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $3.34M 10-Q · filed 2025-08-11 | |||
| 2023-09-30 | $1.56M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |